Atypical Dyschromia in Skin of Color
214822148221482
ABSTRACT
Dyschromia is a concern for many patients, especially persons of color. Postinflammatory hypopigmentation and depigmentation can affect all skin types; however, it is more apparent in those with darker skin. Some members of the dermatology community may not comprehensively understand the mechanisms of these reactions and the extent of the psychosocial effect they have on persons of color …
ABSTRACT
Dyschromia is a concern for many patients, especially persons of color. Postinflammatory hypopigmentation and depigmentation can affect all skin types; however, it is more apparent in those with darker skin. Some members of the dermatology community may not comprehensively understand the mechanisms of these reactions and the extent of the psychosocial effect they have on persons of color … 
JDD authors present the case of a 38-year-old male who reported to their practice with multiple newly developed halos around 26 existing nevi on his trunk. The halo nevi developed after the patient, who lived in the northeast, spent 2 months on a lake in Alabama, with intense heat and sun exposure. This case is remarkable in that it points to ultraviolet exposure as one instigating factor in the … 
At the 2023 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of vitiligo from the renowned researcher and clinician, Dr. John Harris, Professor and Chair of Dermatology at the University of Massachusetts. When a new patient with vitiligo presents to my clinic, I always pull out my phone to consult Dr. Harris’ treatment protocol – I am sure I … 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … 
Hydroquinone is the most commonly used depigmentation agent and is a first-line treatment for melasma.1Hydroquinone was available previously in over-the-counter products and is currently available in prescription formulations with common concentration ranges of 0.4 to 5%. Prescription strengths available in the United States include hydroquinone 2% and 4% cream and hydroquinone 2% gel.2,3 In Septe … 